• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Omar Ford

Omar Ford

Articles

ARTICLES

Wuxi Nextcode to expand genomic data platform through $240M series B round

Sep. 8, 2017
By Omar Ford
Genomic sequencing specialist Wuxi Nextcode Inc. has received a significant cash infusion to further develop what it is calling the "gold standard" for a genomics database. The Shanghai-based company closed on a $240 million series B funding round it started near the end of the first quarter. Previously, the company had raised about $30 million.
Read More

Notable Labs brings in $10M in series A to help personalize cancer treatment therapy

Sep. 7, 2017
By Omar Ford

Teleflex to acquire Neotract for up to $1B to enhance urology offerings

Sep. 6, 2017
By Omar Ford
Teleflex Inc. said it would buy urology specialist Neotract Inc. for up to $1 billion. Specifics of the deal call for Teleflex to offer an upfront cash payment of $725 million at closing and up to an additional $375 million upon the achievement of certain commercial milestones related to sales through the end of 2020. The deal is expected to close within 30 days.
Read More

Apollo's 20-year outcomes for Lap-Band show consistent weight loss in patients

Sep. 5, 2017
By Omar Ford
Twenty year outcome data for Apollo Endosurgery Inc.'s Lap-Band technology shows patients lost 48.2 percent of their excess weight using the device. The Austin, Texas-based company presented data at the 22nd World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders in London, last week.
Read More

Abbott seeks indication for Amplatzer to treat heart defects in pre-term infants

Sep. 1, 2017
By Omar Ford
Abbott Laboratories has initiated a U.S. pivotal clinical study evaluating a modified version of its Amplatzer device designed to correct a common congenital heart defect that occurs in about 80,000 pre-term infants in the U.S. each year.
Read More

Exthera takes two steps forward in path to obtain FDA approval for Seraph

Aug. 31, 2017
By Omar Ford

Renalguard Soultions' device shown to lower risk of contrast-induced acute kidney injury

Aug. 30, 2017
By Omar Ford

Setpoint brings in $30M series D to launch IDE trial for bioelectronic therapy device

Aug. 29, 2017
By Omar Ford

Profound set to bring in C$10M in offering to advance clinical trials for prostate treatment

Aug. 25, 2017
By Omar Ford
Profound Medical Corp. is raising C$10 million (US$7.8 million) through a syndicate of underwriters led by Echelon Wealth Partners Inc., including CIBC Capital Markets. The Mississauga, Ontario-based company is offering an aggregate of 10,000,000 units at a price of C$1 (US80 cents) per unit. Each unit will consist of one common share of Profound (CVE:MRY.P) and one-half of one warrant, with each whole warrant enabling the holder to acquire one common share at a price of $1.40 (US$1.12) per share.
Read More

Caprion partners with FNIH to improve monitoring of AD

Aug. 24, 2017
By Omar Ford
View All Articles by Omar Ford

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 10, 2025.
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe